You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

J. H. Wilmer Eye Institute

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Herpes Zoster Ophthalmicus Trial in Canada, United States (Masked Placebo, Masked Oral Valacyclovir)

Active, not recruiting
  • Herpes Zoster Ophthalmicus
  • Masked Placebo
  • Masked Oral Valacyclovir
  • Birmingham, Alabama
  • +77 more
Jan 17, 2023

Stargardt Disease 1 Trial in Worldwide (Zimura, Sham)

Recruiting
  • Stargardt Disease 1
  • Phoenix, Arizona
  • +41 more
Sep 7, 2022

Glaucoma and Ocular Hypertension Trial in United Kingdom, United States (Low Energy SLT, Standard Energy SLT)

Recruiting
  • Glaucoma and Ocular Hypertension
  • Low Energy SLT
  • Standard Energy SLT
  • Laguna Hills, California
  • +18 more
Jul 12, 2022

Wet Macular Degeneration Trial in Worldwide (Faricimab, Aflibercept, Sham Procedure)

Completed
Has Results
  • Wet Macular Degeneration
  • Mesa, Arizona
  • +159 more
Apr 6, 2022

Meibomian Gland Dysfunction, Dry Eye Trial in Australia, Canada, New Zealand (AZR-MD-001 Low Dose, AZR-MD-001 Mid Dose,

Completed
  • Meibomian Gland Dysfunction
  • Dry Eye
  • AZR-MD-001 Low Dose
  • +3 more
  • Chatswood, New South Wales, Australia
  • +29 more
Nov 23, 2022

Glaucoma, Open-Angle, Ocular Hypertension Trial in Worldwide (Bimatoprost SR, Sham: Applicator Without Needle, Active

Completed
Has Results
  • Glaucoma, Open-Angle
  • Ocular Hypertension
  • Bimatoprost SR
  • +3 more
  • Dothan, Alabama
  • +112 more
Jul 6, 2021

Pro-permeability and Pro-fibrosis Factors in Aqueous of Retinal

Terminated
  • Macular Edema
  • Fibrosis of the Retina
  • Baltimore, Maryland
    Wilmer Eye Institute
Jul 5, 2022

Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy Trial in United States (ALK-001, Placebo)

Recruiting
  • Stargardt Disease
  • +3 more
  • Los Angeles, California
  • +6 more
Feb 15, 2022

Evaluate Functional and Anatomical Progression in Retinitis

Recruiting
  • Retinitis Pigmentosa
    • Baltimore, Maryland
      Wilmer Eye Institute at Johns Hopkins University
    Sep 15, 2022

    Retinitis Pigmentosa Trial in Baltimore (N-Acetyl Cysteine (NAC))

    Completed
    • Retinitis Pigmentosa
    • N-Acetyl Cysteine (NAC)
    • Baltimore, Maryland
      Wilmer Eye Institute, Johns Hopkins
    Sep 15, 2022

    Dry Eye Trial in Baltimore (Sustained Release Dexamethasone, 0.4 mg, E-Caprolactone-L-Lactide copolymer (PCL) punctal plug)

    Recruiting
    • Dry Eye
    • Sustained Release Dexamethasone, 0.4 mg
    • E-Caprolactone-L-Lactide copolymer (PCL) punctal plug
    • Baltimore, Maryland
      Wilmer Eye Institute, Johns Hopkins School of Medicine
    Jan 24, 2022

    Amblyopia Trial in Baltimore (Docosahexaenoic Acid, Placebo Oral Tablet)

    Not yet recruiting
    • Amblyopia
    • Docosahexaenoic Acid
    • Placebo Oral Tablet
    • Baltimore, Maryland
      Johns Hopkins Hospital, Wilmer Eye Institute
    Jan 24, 2022

    Diabetic Retinopathy, Retinal Vein Occlusion, Hypertension,Essential Trial in Baltimore (Swept-Source OCT Angiography,

    Recruiting
    • Diabetic Retinopathy
    • +3 more
    • Swept-Source OCT Angiography
    • +3 more
    • Baltimore, Maryland
      Wilmer Eye Institute
    Aug 10, 2022

    Macular Edema, Retinal Vein Occlusion Trial in Worldwide (suprachoroidal CLS-TA, suprachoroidal sham, IVT aflibercept)

    Terminated
    Has Results
    • Macular Edema
    • Retinal Vein Occlusion
    • suprachoroidal CLS-TA
    • +2 more
    • Peoria, Arizona
    • +109 more
    Mar 18, 2021

    Retinitis Pigmentosa, Visual Impairment, Visual Prosthesis Trial in Baltimore, Laurel (Navigation System for Users of a Visual

    Recruiting
    • Retinitis Pigmentosa
    • +2 more
    • Navigation System for Users of a Visual Prosthesis
    • Baltimore, Maryland
    • +1 more
    Jun 21, 2022

    Novel Functional Eye-Tracking Software Application for

    Recruiting
    • Cancer-related Cognitive Impairment
    • Eye-Tracking
    • Montréal, Quebec, Canada
      McGill University Health Center-Cedar Cancer Center
    May 3, 2022

    Glaucoma, Open-Angle Trial in Oakville (XEN 63)

    Recruiting
    • Glaucoma, Open-Angle
    • XEN 63
    • Oakville, Ontario, Canada
      Prism Eye Institute
    Sep 26, 2022

    Implementation ofNovel Functional Eye-Tracking Biomarker for

    Recruiting
    • Clinically Isolated Syndrome
    • Relapsing Remitting Multiple Sclerosis
    • Eye-tracking
    • Montréal, Quebec, Canada
      Montreal Neurological Institute and Hospital
    Sep 2, 2022

    X-linked Retinoschisis Trial in United States (rAAV2tYF-CB-hRS1)

    Active, not recruiting
    Has Results
    • X-linked Retinoschisis
    • rAAV2tYF-CB-hRS1
    • San Francisco, California
    • +8 more
    Jul 18, 2022

    Study of Retinal Dystrophies Associated With Rare

    Active, not recruiting
    • Inherited Retinal Degeneration
    • Retinitis Pigmentosa
      • Phoenix, Arizona
      • +23 more
      Jan 24, 2023

      Glaucoma Trial in Canada, United States (Beacon Aqueous Microshunt)

      Terminated
      • Glaucoma
      • Beacon Aqueous Microshunt
      • Grand Junction, Colorado
      • +3 more
      Jan 8, 2023

      Glaucoma Trial in United States (Rocklatan® (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%)

      Active, not recruiting
      • Glaucoma
      • Rocklatan® (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%
      • Mission Hills, California
      • +20 more
      Jan 6, 2023

      Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind Trial in Worldwide (Ultevursen, Sham-procedure)

      Recruiting
      • Retinitis Pigmentosa
      • +7 more
      • San Diego, California
      • +14 more
      Jul 29, 2022

      Glaucoma, Depression, Anxiety Trial in London (Breathing Exercises followed by Meditation)

      Not yet recruiting
      • Glaucoma
      • +4 more
      • Breathing Exercises followed by Meditation
      • London, Ontario, Canada
        St. Joseph's Hospital, Ivey Eye Institute
      Jul 21, 2023

      Patients Treated With ranibizUmab for REtinal Vein Occlusion

      Terminated
      • Retinal Vein Occlusion
        • Baltimore, Maryland
          Wilmer Eye Institute
        Oct 8, 2021